The role of teriparatide in sequential and combination therapy of osteoporosis.

Details

Ressource 1Download: 24896070.pdf (414.32 [Ko])
State: Public
Version: Final published version
Serval ID
serval:BIB_E04BD37E015C
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
The role of teriparatide in sequential and combination therapy of osteoporosis.
Journal
Swiss Medical Weekly
Author(s)
Meier C., Lamy O., Krieg M.A., Mellinghoff H.U., Felder M., Ferrari S., Rizzoli R.
ISSN
1424-3997 (Electronic)
ISSN-L
0036-7672
Publication state
Published
Issued date
2014
Peer-reviewed
Oui
Volume
144
Pages
w13952
Language
english
Notes
Publication types: Journal Article Publication Status: epublish PDF: Review Article
Abstract
Osteoporosis is complicated by the occurrence of fragility fractures. Over past years, various treatment options have become available, mostly potent antiresorptive agents such as bisphosphonates and denosumab. However, antiresorptive therapy cannot fully and rapidly restore bone mass and structure that has been lost because of increased remodelling. Alternatively recombinant human parathyroid hormone (rhPTH) analogues do increase the formation of new bone material. The bone formation stimulated by intermittent PTH analogues not only increases bone mineral density (BMD) and bone mass but also improves the microarchitecture of the skeleton, thereby reducing incidence of vertebral and nonvertebral fractures. Teriparatide, a recombinant human PTH fragment available in Switzerland, is reimbursed as second-line treatment in postmenopausal women and men with increased fracture risk, specifically in patients with incident fractures under antiresorptive therapy or patients with glucocorticoid-induced osteoporosis and intolerance to antiresorptives. This position paper focuses on practical aspects in the management of patients on teriparatide treatment. Potential first-line indications for osteoanabolic treatment as well as the benefits and limitations of sequential and combination therapy with antiresorptive drugs are discussed.
Pubmed
Web of science
Open Access
Yes
Create date
08/08/2014 19:40
Last modification date
20/08/2019 16:04
Usage data